Silo Pharma Launches $1M Stock Buyback Initiative; SILO Shares Surge 32.75%

Silo Pharma, Inc. (SILO), an early-stage biopharmaceutical developer, revealed that its board of directors has greenlit a stock buyback program targeting up to $1 million in common stock acquisitions. The announcement triggered an immediate market response, with SILO shares surging 32.75% to $0.37 in premarket trading. The company retains flexibility in execution, with authority to purchase shares on the open market, through privately negotiated transactions, or via other SEC-compliant mechanisms.

Strategic Buyback Program Signals Board Confidence

As of November 13, 2025, the company maintained 13.32 million shares of common stock outstanding, per its most recent quarterly filing for the period ended September 30, 2025. The stock buyback represents a deliberate capital allocation decision, often signaling management’s conviction in the company’s intrinsic value and long-term prospects. Over the past 12 months, SILO has traded within a range of $0.22 to $1.49, with Monday’s close at $0.28 reflecting a 1.82% decline prior to the buyback announcement.

Pipeline Expansion Centered on CNS and PTSD Therapeutics

Silo Pharma’s therapeutic focus spans post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The flagship program, SPC-15—an intranasal prophylactic formulation—targets PTSD and stress-induced anxiety. The company is eyeing FDA submission of an investigational new drug (IND) application this year to initiate a Phase 1 clinical trial, with first-in-human (FIH) SPC-15 dosing anticipated following regulatory clearance.

The broader pipeline includes SP-26 for fibromyalgia and chronic pain management, SPC-14 as an intranasal candidate for Alzheimer’s disease, and SPU-16, a CNS-homing peptide engineered to address multiple sclerosis (MS).

Financial Metrics Underscore R&D Intensity

For the third quarter of 2025, Silo Pharma reported a net loss of $1.20 million, or $0.19 per share, representing a widening from the prior year’s $0.95 million loss (or $0.31 per share). Licence revenue remained flat year-over-year at $0.02 million for the quarter. These figures reflect the substantial investment required to advance early-stage drug candidates through preclinical and clinical development stages, a typical profile for development-stage biopharmaceutical enterprises prioritizing therapeutic innovation over near-term profitability.